Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.93 +2.3%	$5.81	$4.65 ▼ $10.24	$99.13M	0.26	72,995 shs	17,389 shs
CTNM Contineum Therapeutics	$3.93 +2.6%	$4.04	$3.35 ▼ $21.66	$101.67M	0.85	90,813 shs	29,892 shs
CVKD Cadrenal Therapeutics	$11.79 +5.5%	$13.52	$5.70 ▼ $22.90	$23.22M	0.95	43,270 shs	11,075 shs
JSPR Jasper Therapeutics	$3.48 +3.9%	$5.09	$2.27 ▼ $26.05	$51.98M	2.69	399,710 shs	98,029 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-4.30%	-6.91%	+6.24%	+10.08%	-24.51%
CTNM Contineum Therapeutics	+1.59%	-4.49%	-10.72%	-17.10%	-82.39%
CVKD Cadrenal Therapeutics	-8.89%	-13.88%	-18.47%	-33.31%	+1,116,999,900.00%
JSPR Jasper Therapeutics	+1.21%	-8.97%	-40.50%	-15.62%	-84.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	1.7837 of 5 stars	3.5	3.0	1.5	0.8	0.0
CTNM Contineum Therapeutics	3.6817 of 5 stars	3.6	5.0	3.6	0.8	1.3
CVKD Cadrenal Therapeutics	2.9393 of 5 stars	3.5	3.0	3.3	1.7	0.6
JSPR Jasper Therapeutics	3.707 of 5 stars	4.3	4.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$16.50	178.48% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.50	472.52% Upside
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	171.53% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$29.75	755.13% Upside

Current Analyst Ratings Breakdown

Latest CVKD, JSPR, CTNM, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.55M	27.92	N/A	N/A	$2.37 per share	2.50
CTNM Contineum Therapeutics	$50M	2.03	N/A	N/A	$7.66 per share	0.51
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$4.17 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
CVKD Cadrenal Therapeutics	-$10.65M	-$9.26	N/A	N/A	N/A	N/A	-244.94%	-181.94%	8/6/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)

Latest CVKD, JSPR, CTNM, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
8/12/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.28	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	CVKD Cadrenal Therapeutics	-$1.64	-$2.09	-$0.45	-$2.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	8.84	8.84
CTNM Contineum Therapeutics	N/A	21.47	21.47
CVKD Cadrenal Therapeutics	N/A	4.32	4.32
JSPR Jasper Therapeutics	N/A	4.31	4.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
CTNM Contineum Therapeutics	N/A
CVKD Cadrenal Therapeutics	7.92%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
CTNM Contineum Therapeutics	11.30%
CVKD Cadrenal Therapeutics	48.62%
JSPR Jasper Therapeutics	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
CVKD Cadrenal Therapeutics	4	1.97 million	1.01 million	Not Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable

CVKD, JSPR, CTNM, and COYA Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

1 hour ago | prnewswire.com

Contrasting Jasper Therapeutics (NASDAQ:JSPR) & Climb Bio (NASDAQ:CLYM)

July 15 at 4:53 AM | americanbankingnews.com

HC Wainwright Issues Positive Outlook for JSPR Earnings

July 15 at 2:15 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 14 at 10:00 AM | globenewswire.com

HC Wainwright Issues Positive Estimate for JSPR Earnings

July 14 at 2:24 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 12, 2025 | prnewswire.com

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

July 11, 2025 | businesswire.com

Jasper Therapeutics Announces Corporate Reorganization and Other Cost ...

July 11, 2025 | morningstar.comM

Jasper Therapeutics Announces 50% Workforce Reduction and ... - Nasdaq

July 11, 2025 | nasdaq.com

William Blair Analysts Raise Earnings Estimates for JSPR

July 11, 2025 | americanbankingnews.com

BMO Capital Markets Reaffirms "Market Perform" Rating for Jasper Therapeutics (NASDAQ:JSPR)

July 10, 2025 | americanbankingnews.com

UBS Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)

July 9, 2025 | theglobeandmail.com

Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

July 9, 2025 | finanznachrichten.de

Jasper Therapeutics Cutting Half of Staff After Study Setback

July 9, 2025 | marketwatch.com

Jasper halves workforce after dud drug surprise, narrows R&D focus

July 9, 2025 | fiercebiotech.comF

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

July 9, 2025 | globenewswire.com

HC Wainwright Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price

July 9, 2025 | americanbankingnews.com

Jasper Therapeutics (NASDAQ:JSPR) Earns Neutral Rating from Cantor Fitzgerald

July 9, 2025 | americanbankingnews.com

Jasper Therapeutics (NASDAQ:JSPR) Given Market Perform Rating at BMO Capital Markets

July 8, 2025 | marketbeat.com

Jasper Therapeutics Inc News (JSPR) - Investing.com

July 8, 2025 | investing.com

Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $20.00 by Analysts at BTIG Research

July 8, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, JSPR, CTNM, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.92 +0.14 (+2.33%)

As of 10:40 AM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Contineum Therapeutics NASDAQ:CTNM

$3.93 +0.10 (+2.61%)

As of 10:39 AM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Cadrenal Therapeutics NASDAQ:CVKD

$11.78 +0.62 (+5.51%)

As of 10:43 AM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Jasper Therapeutics NASDAQ:JSPR

$3.48 +0.13 (+3.85%)

As of 10:43 AM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time